NEW YORK (GenomeWeb News) – The University of Connecticut has inked a partnership with KeraFast to make stem cells developed at the university available globally.

KeraFast will market two stem cells lines created in 2009 from skin cells taken from patients with deletions of sections of chromosome 15 who develop Angelman Syndrome and Prader-Willi Syndrome. The stem cell lines were developed in the laboratories of UConn researchers Stormy Chamberlain and Marc Lalande.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A research duo estimates in PLOS One the number of papers that have used misidentified cell lines.

UK's National Institute for Health and Care Excellence approves GlaxoSmithKline's SCID gene therapy despite cost.

Science reports that Brazilian researchers are petitioning for the reversal of budget cuts.

In PLOS this week: gene flow patterns in common ash, guidelines for using morpholinos in zebrafish, and more.